$CTMX
CytomX Therapeutics, Inc.

2018 Q2 Form 10-Q Financial Statement

#000156459018020448 Filed on August 08, 2018

View on sec.gov

Income Statement

Concept 2018 Q2 2017 Q2
Revenue $21.34M $8.752M
YoY Change 143.81% 182.87%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.040M $6.050M
YoY Change 49.42% 30.11%
% of Gross Profit
Research & Development $25.55M $28.08M
YoY Change -8.99% 120.9%
% of Gross Profit
Depreciation & Amortization $500.0K $400.0K
YoY Change 25.0% 0.0%
% of Gross Profit
Operating Expenses $34.60M $28.08M
YoY Change 23.22% 61.82%
Operating Profit -$13.26M
YoY Change
Interest Expense $1.540M $357.0K
YoY Change 331.37% -23.23%
% of Operating Profit
Other Income/Expense, Net $60.00K -$174.0K
YoY Change -134.48% 58.18%
Pretax Income -$11.66M -$25.19M
YoY Change -53.73% 77.73%
Income Tax $1.800M $30.00K
% Of Pretax Income
Net Earnings -$13.45M -$25.22M
YoY Change -46.67% 77.88%
Net Earnings / Revenue -63.02% -288.12%
Basic Earnings Per Share
Diluted Earnings Per Share -$345.2K -$685.7K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q2 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $335.1M $335.9M
YoY Change -0.24% 71.55%
Cash & Equivalents $132.9M $273.8M
Short-Term Investments $202.2M $63.10M
Other Short-Term Assets $6.400M $4.600M
YoY Change 39.13% 35.29%
Inventory
Prepaid Expenses
Receivables $25.10M $200.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $366.7M $340.7M
YoY Change 7.63% 70.69%
LONG-TERM ASSETS
Property, Plant & Equipment $5.500M $4.300M
YoY Change 27.91% 26.47%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.300M $4.200M
YoY Change -45.24% 250.0%
Total Long-Term Assets $10.20M $11.20M
YoY Change -8.93% 53.42%
TOTAL ASSETS
Total Short-Term Assets $366.7M $340.7M
Total Long-Term Assets $10.20M $11.20M
Total Assets $376.9M $351.9M
YoY Change 7.1% 70.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.200M $6.400M
YoY Change -34.38% 357.14%
Accrued Expenses $24.80M $7.500M
YoY Change 230.67% 2.74%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $83.20M $60.60M
YoY Change 37.29% 172.97%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $252.6M $238.4M
YoY Change 5.96% 187.58%
Total Long-Term Liabilities $252.6M $238.4M
YoY Change 5.96% 187.58%
TOTAL LIABILITIES
Total Short-Term Liabilities $83.20M $60.60M
Total Long-Term Liabilities $252.6M $238.4M
Total Liabilities $335.8M $299.6M
YoY Change 12.08% 183.44%
SHAREHOLDERS EQUITY
Retained Earnings -$209.8M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $41.13M $52.24M
YoY Change
Total Liabilities & Shareholders Equity $376.9M $351.9M
YoY Change 7.12% 70.06%

Cashflow Statement

Concept 2018 Q2 2017 Q2
OPERATING ACTIVITIES
Net Income -$13.45M -$25.22M
YoY Change -46.67% 77.88%
Depreciation, Depletion And Amortization $500.0K $400.0K
YoY Change 25.0% 0.0%
Cash From Operating Activities -$26.60M $173.2M
YoY Change -115.36% 1003.18%
INVESTING ACTIVITIES
Capital Expenditures -$800.0K -$400.0K
YoY Change 100.0% 0.0%
Acquisitions
YoY Change
Other Investing Activities $17.50M $13.60M
YoY Change 28.68% -164.45%
Cash From Investing Activities $16.70M $13.30M
YoY Change 25.56% -161.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 700.0K 700.0K
YoY Change 0.0% 250.0%
NET CHANGE
Cash From Operating Activities -26.60M 173.2M
Cash From Investing Activities 16.70M 13.30M
Cash From Financing Activities 700.0K 700.0K
Net Change In Cash -9.200M 187.2M
YoY Change -104.91% -3442.86%
FREE CASH FLOW
Cash From Operating Activities -$26.60M $173.2M
Capital Expenditures -$800.0K -$400.0K
Free Cash Flow -$25.80M $173.6M
YoY Change -114.86% 978.26%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28076000
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9042000
us-gaap Operating Income Loss
OperatingIncomeLoss
-28887000
CY2017Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
357000
us-gaap Investment Income Interest
InvestmentIncomeInterest
2915000
CY2017Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-174000
CY2018Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11656000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
179675000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41228000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
154109000
CY2017Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.69
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.75
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38961021
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36780897
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38805317
CY2018Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
50000
CY2017Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-10000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-84000
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13397000
CY2017Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25226000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29024000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
1000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
73000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
802000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
764000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
643000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-337000
us-gaap Share Based Compensation
ShareBasedCompensation
7849000
us-gaap Share Based Compensation
ShareBasedCompensation
5757000
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
26000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
14998000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2001000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-127000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1878000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
683000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1619000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1268000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
99630000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
54183000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
94513000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
68000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6736000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
12549000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3324000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
20000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
267000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-429000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
79000
ctmx Increase Decrease In Accrued Liabilities Income Tax Payable And Other Liabilities Noncurrent
IncreaseDecreaseInAccruedLiabilitiesIncomeTaxPayableAndOtherLiabilitiesNoncurrent
11303000
ctmx Increase Decrease In Accrued Liabilities Income Tax Payable And Other Liabilities Noncurrent
IncreaseDecreaseInAccruedLiabilitiesIncomeTaxPayableAndOtherLiabilitiesNoncurrent
-233000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-14347000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1557000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3324000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1557000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-44640000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
168215000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
178465000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
105562000
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
133825000
CY2017Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
273777000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
826000
us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Description of the Business</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CytomX Therapeutics, Inc. (the &#8220;Company&#8221;) is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapeutics. The Company is pioneering a novel class of investigational antibody therapeutics, based on its Probody&#8482; therapeutic technology platform, for the treatment of cancer. The Probody therapeutic approach is designed to more specifically target antibody therapeutics to the tumor microenvironment and reduce drug activity in healthy tissue and in circulation. The Company is located in South San Francisco, California and was incorporated in the state of Delaware in September 2010.</p></div>
CY2017Q4 ctmx Accrued Research And Clinical Current
AccruedResearchAndClinicalCurrent
10068000
CY2018Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3089000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4526000
CY2018Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1827000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1523000
CY2018Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
260000
ctmx Contract With Customer Liability Accounting Standards Codification606 Adoption Adjustment
ContractWithCustomerLiabilityAccountingStandardsCodification606AdoptionAdjustment
10912000
us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
21000000
us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
9901000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
265000
CY2017Q4 us-gaap Deferred Revenue
DeferredRevenue
305263000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</p></div>
us-gaap Revenue Recognition Deferred Revenue
RevenueRecognitionDeferredRevenue
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contract Balances</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer payments are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional.</p></div>
CY2018Q2 ctmx Accrued Research And Clinical Current
AccruedResearchAndClinicalCurrent
19592000
CY2018Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
334756000
CY2018Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
151000
CY2018Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
334605000
CY2017Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
67000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
25446000
CY2018Q2 us-gaap Deferred Revenue
DeferredRevenue
301828000
us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
31900000
CY2018Q2 ctmx Royalty Obligations Future Minimum Payments Due
RoyaltyObligationsFutureMinimumPaymentsDue
150000
ctmx License Termination Period
LicenseTerminationPeriod
P60D
CY2018Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4161000
CY2017Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3009000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7849000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5757000
CY2018Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7351681
CY2017Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6907038
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7329531
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7048959
CY2018Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.154
CY2017Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.111
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2018Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
ctmx Tax Cuts And Jobs Act Accounting Complete True False
TaxCutsAndJobsActAccountingCompleteTrueFalse
false
CY2018Q2 ctmx Tax Cuts And Jobs Act Incomplete Accounting Change In Tax Rate Provisional Income Tax Expense Benefit
TaxCutsAndJobsActIncompleteAccountingChangeInTaxRateProvisionalIncomeTaxExpenseBenefit
0
ctmx Tax Cuts And Jobs Act Incomplete Accounting Change In Tax Rate Provisional Income Tax Expense Benefit
TaxCutsAndJobsActIncompleteAccountingChangeInTaxRateProvisionalIncomeTaxExpenseBenefit
0

Files In Submission

Name View Source Status
0001564590-18-020448-index-headers.html Edgar Link pending
0001564590-18-020448-index.html Edgar Link pending
0001564590-18-020448.txt Edgar Link pending
0001564590-18-020448-xbrl.zip Edgar Link pending
ctmx-10q_20180630.htm Edgar Link pending
ctmx-20180630.xml Edgar Link completed
ctmx-20180630.xsd Edgar Link pending
ctmx-20180630_cal.xml Edgar Link unprocessable
ctmx-20180630_def.xml Edgar Link unprocessable
ctmx-20180630_lab.xml Edgar Link unprocessable
ctmx-20180630_pre.xml Edgar Link unprocessable
ctmx-ex101_66.htm Edgar Link pending
ctmx-ex311_8.htm Edgar Link pending
ctmx-ex312_11.htm Edgar Link pending
ctmx-ex321_6.htm Edgar Link pending
ctmx-ex322_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gu1zxbi5ajas000001.jpg Edgar Link pending
gu1zxbi5ajas000002.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending